BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lesueur P, Chevalier F, El-habr EA, Junier M, Chneiweiss H, Castera L, Müller E, Stefan D, Saintigny Y. Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation. Sci Rep 2018;8. [DOI: 10.1038/s41598-018-22022-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Choi PJ, Cooper E, Schweder P, Mee E, Turner C, Faull R, Denny WA, Dragunow M, Park TI, Jose J. PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines. Bioorg Med Chem Lett 2020;30:127252. [PMID: 32527552 DOI: 10.1016/j.bmcl.2020.127252] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Beggs R, Yang ES. Targeting DNA repair in precision medicine. Adv Protein Chem Struct Biol 2019;115:135-55. [PMID: 30798930 DOI: 10.1016/bs.apcsb.2018.10.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hwang K, Lee JH, Kim SH, Go KO, Ji SY, Han JH, Kim CY. The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model. In Vivo 2021;35:2015-23. [PMID: 34182476 DOI: 10.21873/invivo.12470] [Reference Citation Analysis]
4 Vares G, Jallet V, Matsumoto Y, Rentier C, Takayama K, Sasaki T, Hayashi Y, Kumada H, Sugawara H. Functionalized mesoporous silica nanoparticles for innovative boron-neutron capture therapy of resistant cancers. Nanomedicine 2020;27:102195. [PMID: 32278101 DOI: 10.1016/j.nano.2020.102195] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
5 Thariat J, Valable S, Laurent C, Haghdoost S, Pérès EA, Bernaudin M, Sichel F, Lesueur P, Césaire M, Petit E, Ferré AE, Saintigny Y, Skog S, Tudor M, Gérard M, Thureau S, Habrand JL, Balosso J, Chevalier F. Hadrontherapy Interactions in Molecular and Cellular Biology. Int J Mol Sci 2019;21:E133. [PMID: 31878191 DOI: 10.3390/ijms21010133] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Rizvi A, Merlin MA, Shah GM. Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications. Eur J Pharmacol 2021;911:174546. [PMID: 34600907 DOI: 10.1016/j.ejphar.2021.174546] [Reference Citation Analysis]
7 Testa U, Castelli G, Pelosi E. Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. Med Sci (Basel) 2018;6:E85. [PMID: 30279357 DOI: 10.3390/medsci6040085] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
8 Schulz A, Meyer F, Dubrovska A, Borgmann K. Cancer Stem Cells and Radioresistance: DNA Repair and Beyond. Cancers (Basel) 2019;11:E862. [PMID: 31234336 DOI: 10.3390/cancers11060862] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 26.0] [Reference Citation Analysis]
9 Zhang J, Si J, Gan L, Zhou R, Guo M, Zhang H. Harnessing the targeting potential of differential radiobiological effects of photon versus particle radiation for cancer treatment. J Cell Physiol 2021;236:1695-711. [PMID: 32691425 DOI: 10.1002/jcp.29960] [Reference Citation Analysis]
10 Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers. Expert Opin Ther Targets 2019;23:773-85. [PMID: 31394942 DOI: 10.1080/14728222.2019.1654458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
11 Matsumoto Y, Fukumitsu N, Ishikawa H, Nakai K, Sakurai H. A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond. J Pers Med 2021;11:825. [PMID: 34442469 DOI: 10.3390/jpm11080825] [Reference Citation Analysis]
12 Hutóczki G, Virga J, Birkó Z, Klekner A. Novel Concepts of Glioblastoma Therapy Concerning Its Heterogeneity. Int J Mol Sci 2021;22:10005. [PMID: 34576168 DOI: 10.3390/ijms221810005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zeniou M, Nguekeu-Zebaze L, Dantzer F. Therapeutic considerations of PARP in stem cell biology: Relevance in cancer and beyond. Biochem Pharmacol 2019;167:107-15. [PMID: 31202733 DOI: 10.1016/j.bcp.2019.06.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
14 Gupta SK, Smith EJ, Mladek AC, Tian S, Decker PA, Kizilbash SH, Kitange GJ, Sarkaria JN. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. Front Oncol 2018;8:670. [PMID: 30723695 DOI: 10.3389/fonc.2018.00670] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
15 Olivares-Urbano MA, Griñán-Lisón C, Marchal JA, Núñez MI. CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer. Cells 2020;9:E1651. [PMID: 32660072 DOI: 10.3390/cells9071651] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
16 Gouazé-andersson V, Cohen-jonathan Moyal E. New Avenues in Radiotherapy of Glioblastoma: from Bench to Bedside. Curr Treat Options Neurol 2020;22. [DOI: 10.1007/s11940-020-00654-0] [Reference Citation Analysis]
17 Lesueur P, Lequesne J, Grellard JM, Dugué A, Coquan E, Brachet PE, Geffrelot J, Kao W, Emery E, Berro DH, Castera L, Goardon N, Lacroix J, Lange M, Capel A, Leconte A, Andre B, Léger A, Lelaidier A, Clarisse B, Stefan D. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer 2019;19:198. [PMID: 30832617 DOI: 10.1186/s12885-019-5413-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 14.0] [Reference Citation Analysis]
18 Mooney J, Bernstock JD, Ilyas A, Ibrahim A, Yamashita D, Markert JM, Nakano I. Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma. World Neurosurg 2019;129:90-100. [PMID: 31152883 DOI: 10.1016/j.wneu.2019.05.205] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
19 Césaire M, Ghosh U, Austry JB, Muller E, Cammarata FP, Guillamin M, Caruso M, Castéra L, Petringa G, Cirrone GAP, Chevalier F. Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation. J Bone Oncol 2019;17:100246. [PMID: 31312595 DOI: 10.1016/j.jbo.2019.100246] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Sousa JF, Serafim RB, Freitas LM, Fontana CR, Valente V. DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance. Genet Mol Biol 2019;43:e20190066. [PMID: 31930277 DOI: 10.1590/1678-4685-GMB-2019-0066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
21 Godoy PRDV, Pour Khavari A, Rizzo M, Sakamoto-Hojo ET, Haghdoost S. Targeting NRF2, Regulator of Antioxidant System, to Sensitize Glioblastoma Neurosphere Cells to Radiation-Induced Oxidative Stress. Oxid Med Cell Longev 2020;2020:2534643. [PMID: 32617133 DOI: 10.1155/2020/2534643] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
22 Choi PJ, Park TI, Cooper E, Dragunow M, Denny WA, Jose J. Heptamethine Cyanine Dye Mediated Drug Delivery: Hype or Hope. Bioconjugate Chem 2020;31:1724-39. [DOI: 10.1021/acs.bioconjchem.0c00302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
23 Bighetti-Trevisan RL, Sousa LO, Castilho RM, Almeida LO. Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics. Stem Cells Int 2019;2019:9618065. [PMID: 31781251 DOI: 10.1155/2019/9618065] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
24 Xu L, Lin X, Zheng Y, Zhou H. Silencing of heat shock protein 27 increases the radiosensitivity of non‑small cell lung carcinoma cells. Mol Med Rep 2019;20:613-21. [PMID: 31115576 DOI: 10.3892/mmr.2019.10263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Ali MY, Oliva CR, Noman ASM, Allen BG, Goswami PC, Zakharia Y, Monga V, Spitz DR, Buatti JM, Griguer CE. Radioresistance in Glioblastoma and the Development of Radiosensitizers. Cancers (Basel) 2020;12:E2511. [PMID: 32899427 DOI: 10.3390/cancers12092511] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
26 Lee TW, Wong WW, Dickson BD, Lipert B, Cheng GJ, Hunter FW, Hay MP, Wilson WR. Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia. Int J Radiat Biol 2019;95:1597-612. [PMID: 31490091 DOI: 10.1080/09553002.2019.1664787] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
27 Lakomy DS, Urbauer DL, Westin SN, Lin LL. Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers. Clin Transl Radiat Oncol 2020;21:56-61. [PMID: 31993510 DOI: 10.1016/j.ctro.2019.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Konings K, Vandevoorde C, Baselet B, Baatout S, Moreels M. Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance. Front Oncol 2020;10:128. [PMID: 32117774 DOI: 10.3389/fonc.2020.00128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
29 Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate Glioblastoma: clinical challenges and advances. Clin Transl Med 2018;7:33. [PMID: 30327965 DOI: 10.1186/s40169-018-0211-8] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 19.0] [Reference Citation Analysis]
30 Ning J, Wakimoto H. Therapeutic Application of PARP Inhibitors in Neuro-Oncology. Trends Cancer 2020;6:147-59. [PMID: 32061304 DOI: 10.1016/j.trecan.2019.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
31 Abdul KU, Houweling M, Svensson F, Narayan RS, Cornelissen FMG, Küçükosmanoglu A, Metzakopian E, Watts C, Bailey D, Wurdinger T, Westerman BA. WINDOW consortium: A path towards increased therapy efficacy against glioblastoma. Drug Resist Updat 2018;40:17-24. [PMID: 30439622 DOI: 10.1016/j.drup.2018.10.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
32 Ma S, Guo Z, Wang B, Yang M, Yuan X, Ji B, Wu Y, Chen S. A Computational Framework to Identify Biomarkers for Glioma Recurrence and Potential Drugs Targeting Them. Front Genet 2022;12:832627. [DOI: 10.3389/fgene.2021.832627] [Reference Citation Analysis]
33 Tinganelli W, Durante M. Carbon Ion Radiobiology. Cancers (Basel) 2020;12:E3022. [PMID: 33080914 DOI: 10.3390/cancers12103022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
34 Schnöller LE, Albrecht V, Brix N, Nieto AE, Fleischmann DF, Niyazi M, Hess J, Belka C, Unger K, Lauber K, Orth M. Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy. Radiat Oncol 2022;17:79. [PMID: 35440003 DOI: 10.1186/s13014-022-02052-z] [Reference Citation Analysis]
35 Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res 2021;171:105780. [PMID: 34302977 DOI: 10.1016/j.phrs.2021.105780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhang P, Yu B, Jin X, Zhao T, Ye F, Liu X, Li P, Zheng X, Chen W, Li Q. Therapeutic Efficacy of Carbon Ion Irradiation Enhanced by 11-MUA-Capped Gold Nanoparticles: An in vitro and in vivo Study. Int J Nanomedicine 2021;16:4661-74. [PMID: 34262274 DOI: 10.2147/IJN.S313678] [Reference Citation Analysis]
37 Vares G, Ahire V, Sunada S, Ho Kim E, Sai S, Chevalier F, Romeo PH, Yamamoto T, Nakajima T, Saintigny Y. A multimodal treatment of carbon ions irradiation, miRNA-34 and mTOR inhibitor specifically control high-grade chondrosarcoma cancer stem cells. Radiother Oncol 2020;150:253-61. [PMID: 32717360 DOI: 10.1016/j.radonc.2020.07.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Jonuscheit S, Jost T, Gajdošová F, Wrobel M, Hecht M, Fietkau R, Distel L. PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation. Genes (Basel) 2021;12:849. [PMID: 34073147 DOI: 10.3390/genes12060849] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Abad E, Graifer D, Lyakhovich A. DNA damage response and resistance of cancer stem cells. Cancer Lett 2020;474:106-17. [PMID: 31968219 DOI: 10.1016/j.canlet.2020.01.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
40 Harland A, Liu X, Ghirardello M, Galan MC, Perks CM, Kurian KM. Glioma Stem-Like Cells and Metabolism: Potential for Novel Therapeutic Strategies. Front Oncol 2021;11:743814. [PMID: 34532295 DOI: 10.3389/fonc.2021.743814] [Reference Citation Analysis]
41 Pepper NB, Stummer W, Eich HT. The use of radiosensitizing agents in the therapy of glioblastoma multiforme-a comprehensive review. Strahlenther Onkol 2022. [PMID: 35503461 DOI: 10.1007/s00066-022-01942-1] [Reference Citation Analysis]